FDA approves zolbetuximab for CLDN18.2-positive gastric and gastroesophageal junction cancer
Evidence stage: High-Certainty EvidenceRegulatory status: FDA Approved
In two separate, randomized, double-blind, phase 3 trials (SPOTLIGHT and GLOW), adding zolbetuximab to first-line chemotherapy significantly extended both progression-free survival and overall survival, compared with chemotherapy alone, in patients…
Primary source cited
Last reviewed